Core Viewpoint - Vaisala Corporation has executed a share repurchase, acquiring 900 shares at an average price of 46.9556 EUR per share, totaling a cost of 42,260.04 EUR, which increases its total holdings to 141,384 shares [1]. Group 1: Share Repurchase Details - The share repurchase occurred on August 20, 2025, in compliance with European regulations [1]. - The average price per share during the buyback was 46.9556 EUR [1]. - The total cost of the repurchase was 42,260.04 EUR [1]. Group 2: Company Overview - Vaisala Corporation is a global leader in measurement instruments and intelligence for climate action, focusing on improving resource efficiency and energy transition [2]. - The company has nearly 90 years of innovation and employs around 2,500 experts dedicated to environmental measures [2]. - Vaisala's series A shares are listed on the Nasdaq Helsinki stock exchange [2].

Core Viewpoint - The U.S. FDA has extended the target action dates for Regeneron Pharmaceuticals' EYLEA HD regulatory submissions to the fourth quarter of 2025 due to major amendments resulting from a recent inspection of a third-party manufacturer [1][2] Group 1: Regulatory Updates - The FDA's extension of review periods was prompted by significant information provided after an inspection at Catalent Indiana LLC, which is now owned by Novo Nordisk A/S [2] - Novo Nordisk submitted a comprehensive response to the FDA in early August 2025 to address the observations noted during the inspection [2] - EYLEA HD remains available in the U.S. through vial administration, with approved dosing intervals ranging from every 8 to 16 weeks for various conditions [3] Group 2: Product Information - EYLEA HD is a vascular endothelial growth factor inhibitor developed to provide comparable efficacy and safety to EYLEA but with fewer injections [5] - EYLEA HD is approved in the U.S. for treating patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) [8] - EYLEA HD is being jointly developed by Regeneron and Bayer AG, with Regeneron holding exclusive rights in the U.S. and Bayer having exclusive marketing rights outside the U.S. [6] Group 3: Company Overview - Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases, leveraging its unique ability to translate science into medicine [11] - The company has a robust research and development program in ophthalmology, aiming to address additional serious eye diseases [7] - Regeneron utilizes proprietary technologies to accelerate drug development and is committed to innovative solutions for patients [12]

Core Viewpoint - goeasy Ltd. successfully closed an upsized offering of senior unsecured notes, reflecting strong market demand and confidence in its business [1][3] Group 1: Offering Details - The company closed an offering of US$450 million in senior unsecured notes due 2031, increased from an initial US$400 million [1] - Additionally, goeasy issued C$175 million in 6.000% senior unsecured notes due 2030, up from C$100 million at the initial offering [1] - The New CAD Notes were issued at a price of C$997.50 per C$1,000 principal amount, plus accrued interest from May 15, 2025 [1] Group 2: Financial Strategy - goeasy entered into a currency swap agreement to reduce the Canadian dollar equivalent cost of borrowing on the USD Notes to 6.106% per annum, down from a coupon of 6.875% [2] - The net proceeds from the sale of the notes will be used to partially repay indebtedness under secured facilities and for general corporate purposes [2] Group 3: Company Overview - goeasy Ltd. is a leading consumer lender in Canada, providing financial services to individuals with near to non-prime credit scores [1] - The company operates through its easyhome, easyfinancial, and LendCare brands, offering a variety of financial products including unsecured and secured installment loans [3] - goeasy has a total funding capacity of C$2.3 billion to support its growth plans [3] Group 4: Awards and Recognition - goeasy has received several awards for its corporate culture and growth, including recognition from TIME Magazine and Waterstone Canada [4] - The company has raised and donated over C$6.5 million to support local charities and partnerships [4]

Austin, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- DBGI Corp. (Ticker: [NASDAQ:DBGI] a publicly traded company specializing in eCommerce and Fashion today announced it will commence trading on The Nasdaq Capital Market ("Nasdaq") under its current ticker symbol “DBGI” on Wednesday, August 20, 2025. The uplisting to Nasdaq marks a key milestone in the Company’s evolution, designed to enhance investor visibility, increase liquidity, and allow Digital Brands Group to pursue its growth strategy. The Company belie ...

Company Overview - DBGI Corp. specializes in eCommerce and Fashion, offering a wide variety of apparel through multiple brands on both direct-to-consumer and wholesale bases [3] - The company operates under a digitally native-first vertical brand model, focusing on personalized content and customer engagement to enhance "closet share" [3] Nasdaq Uplisting - The company announced its uplisting to The Nasdaq Capital Market under the ticker symbol "DBGI," effective August 20, 2025 [1][2] - This transition is aimed at enhancing investor visibility, increasing liquidity, and supporting the company's growth strategy, positioning it for long-term value creation for shareholders [2] Business Model and Strategy - Digital Brands Group continues to operate under its existing business model while leveraging customer data and purchase history to create targeted marketing strategies [3] - The company emphasizes the importance of maintaining its current operational structure while pursuing growth opportunities in the apparel market [2]

Core Insights - VENU is positioning itself as a next-generation entertainment powerhouse, aiming to sell over 20 million tickets annually and generate $2 billion in ticket sales volume within a few years [1][4]. Digital Platform and Blockchain Integration - VENU plans to launch a digital, blockchain-powered platform in early 2026, which will include tokenized digital memberships, fan rewards, and soft ticketing services, marking its entry into real-world asset (RWA) tokenization [2][5]. - The blockchain initiative is a core part of VENU's strategy, aiming to enhance digital engagement with fans and redefine their interaction with live music and events [3][5]. Venue Expansion Plans - VENU is aggressively expanding its physical venue footprint, with plans to open three new amphitheaters in 2026 and a target of 25 amphitheaters and 15 indoor entertainment complexes by 2030, which will provide over 350,000 seats [4][9]. - This expansion is expected to position VENU as one of the largest players in the U.S. live entertainment market, following only a major national operator and a leading secondary market platform [4]. Market Position and Institutional Interest - VENU is becoming a significant player at the intersection of entertainment, real estate, and blockchain innovation, with growing institutional interest, including a new position from Vanguard Group [7]. - The company aims to unify benefits across its properties and create a direct channel to superfans and partners through its digital engagement layer [7].

Core Viewpoint - Keros Therapeutics has received Orphan Drug designation from the FDA for KER-065, aimed at treating Duchenne muscular dystrophy (DMD), highlighting the significant unmet medical need in this area [1][2]. Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [5]. - The company is recognized for its expertise in the TGF-ß family of proteins, which are crucial for the growth, repair, and maintenance of various tissues, including blood, bone, skeletal muscle, adipose, and heart tissue [5]. Product Information - KER-065 is a novel ligand trap designed to inhibit the biological effects of myostatin and activin A, promoting skeletal muscle regeneration, increasing muscle size and strength, reducing body fat, and enhancing bone strength [3]. - The product is initially focused on treating DMD, a severe condition characterized by muscle degeneration due to the lack of functional dystrophin protein [4]. Disease Context - Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy, leading to muscle degeneration and premature death, affecting approximately one in every 3,500 male births worldwide [4]. - The absence of dystrophin results in increased susceptibility of muscle cells to damage, progressive muscle cell death, and replacement with fibrotic and fatty tissue, ultimately causing loss of muscle strength and function [4]. Regulatory Milestone - The Orphan Drug designation provides Keros with several benefits, including tax credits for clinical testing, waivers or reductions in FDA application fees, and seven years of market exclusivity upon approval [2].

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® data demonstrate new cardiometabolic benefits (improvements in heart and metabolic health) in people living with type 2 diabetes (SOUL and STRIDE studies)New insights into the role of inflammation in cardiovascular disease on mortality and major cardiovascular events in people living with inflammation in the hear ...

Core Viewpoint - Uniti has been recognized as the 1 Military Friendly® Company for 2025 in the $1 billion-to-$5 billion annual revenue category, highlighting its commitment to supporting military service members, veterans, and their families [1][2]. Company Recognition - Uniti, which includes segments formerly part of Windstream, has been acknowledged for creating meaningful career paths and community support for military personnel [2]. - The company has achieved a top 10 Military Friendly® Company status for four consecutive years, reflecting its ongoing dedication to hiring and retaining military veterans [3]. Leadership Statement - Jennifer Ragsdale, executive vice president, emphasized the vital role that veterans and their spouses play in Uniti's mission to provide critical communication services to various customer segments [3]. Company Overview - Uniti is a leading fiber provider focused on enabling mission-critical connectivity across the United States, serving over a million consumers and businesses [5]. - The company operates under several brands, including Uniti Wholesale, Kinetic, Uniti Fiber, and Uniti Solutions, offering a broad portfolio of fast and reliable communication services [5].

Report on first half of 2025for ROCKWOOL A/SRelease no. 50 – 2025to Nasdaq Copenhagen 20 August 2025 While adjusting our outlook to reflect market uncertainty, we stay committed to investing for long-term value creation Highlights Revenue in H1 2025 reached 1,947 MEUR, an increase of one percent measured in both local currencies and reported figures compared to last year. The 2024 acquisitions had a two-percentage point positive impact in H1 2025 compared to last year.Revenue in Q2 2025 reached 988 MEUR, a ...